The company estimates that the vaccine's sales in Russia will total several hundred thousand dollars this year.
Kamada Ltd. (TASE: KMDA) has received its first Russian orders for its KamRho-D IM vaccine to prevent Rh hemolytic disease (hemolysis) in fetuses. The company estimates that the product's sales in Russia will total several hundred thousand dollars by the end of 2010. Kamada completed registration of the vaccine in Russia in February.
Rh hemolytic anemia is caused by incompatibility between a mother and fetus's blood types. Kamada estimates that 15% of women require treatment to prevent this autoimmune condition.
Kamada already sells KamRho in Israel and in seven additional countries in Africa, Asia, and Latin America.
Kamada's share price rose 4.7% in early trading to NIS 20.80, giving a market cap of NIS 543 million
Published by Globes [online], Israel business news - www.globes-online.com - on June 2, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010